PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies
Retrieved on:
Wednesday, September 20, 2023
Vaccine, Infection, National Institute of Allergy and Infectious Diseases, European Scientific Cooperative on Phytotherapy, Antigen, Cleveland Clinic, Human, Biotechnology, Vaccination, PDSB, Ferret, NG2, HAI, Weight loss, H3N2, Doctor of Philosophy, Mock, Protein, CD8, Animal, PDS, MD, CD4, Conference, COBRA, H1N1
“We are encouraged that PDS0202 has demonstrated activity in generating protective hemagglutination inhibition assay (HAI) antibody responses in pre-immune ferret studies, which are the gold standard in influenza vaccine testing.
Key Points:
- “We are encouraged that PDS0202 has demonstrated activity in generating protective hemagglutination inhibition assay (HAI) antibody responses in pre-immune ferret studies, which are the gold standard in influenza vaccine testing.
- In addition to active neutralization of various influenza strains, the data demonstrated that PDS0202 prevented illness, weight loss and importantly protected the lungs of vaccinated animals from H1N1,” said Dr. Ross.
- PDS0202 combines PDS Biotech’s Infectimune® novel investigational immune activating platform with proprietary Computationally Optimized Broadly Reactive Antigens (COBRA) influenza antigens.
- This robust immune response to the COBRA antigens suggests strong potential for PDS0202 as a broad and long-term protecting universal influenza vaccine.